Cipandrol – Balkan Testosterone C
The DCI of the active substance
1 ml solution contains:
active substance: Testosterone Cypionate 200 mg;
excipients: benzyl alcohol, benzyl benzoate, peach oil.
Description of the drug
The oily, transparent solution, from light-yellow to yellow, with a characteristic odor.
Testosterone Cypionate is a testosterone ester. Testosterone is the primary androgen hormone synthesized and released by the testes. It is responsible for the growth and development of male sexual organs and secondary sexual characteristics (maturation of the prostate, seminal vesicles, penis, and scrotum), male distribution of the hair (without, pubis, chest), development of the larynx, body musculature and fat distribution. It retains nitrogen, sodium, potassium, and phosphorus, increases anabolism, and reduces protein catabolism. A premature increase in plasma testosterone concentration during the prepubertal period causes epiphyses to close and growth to stop. It stimulates the production of erythropoietin and erythrocytes. Through feedback mechanism, it inhibits the secretion of luteinizing hormone and follicle-stimulating pituitary and causes suppression of spermatogenesis. In women, it inhibits the pituitary gonotrophic function, ovarian function, mammary glands, endometrial atrophy. Due to estrogen-antagonistic action, it is used in the treatment of uterine myoma, endometriosis, breast cancer. Manifest beneficial action during the climacteric period.
Testosterone Cypionate is absorbed slowly. The maximum plasma concentration is achieved over 72 hours after intramuscular administration. Duration of action 2 – 4 weeks. In the blood, about 98% of testosterone is coupled with a specific fraction of globulin, which binds testosterone and estradiol. Biotransformation occurs in the liver up to various 17-ketosteroids, which after conjugation with glucuronic or sulfuric acid are eliminated with urine (about 90%). Approximately 6% of the absorbed preparation is removed with the feces in free form.
In men – hormone replacement therapy in disorders caused by testosterone deficiency:
- retaining sexual maturation;
- eunuchoidism, undevelopment of the genital organs;
- male climax impotence (decreased libido and physical and intellectual activity);
- post-castration syndrome (androgenic deficit after castration);
- osteoporosis caused by androgen insufficiency.
Dosage and Mode of Administration
Deep intramuscular. The dose is individually determined to depend on the disease, gender, age, clinical efficacy.
Usually, in adults, it is given intramuscularly 50 – 200 mg once every 2-4 weeks. The dose of 400 mg per month is not recommended. The duration of treatment is determined individually.
In hypogonadism in men like eunuchoidism, the recommended doses are 50 – 400 mg every 2-4 weeks.
In case of retention of sexual maturation, it is administered 50 to 200 mg every 2-4 weeks for 4-6 months.
In breast cancer inoperable in women: 200-400 mg every 2-4 weeks.
The preparation is not given intravenously!